ZEVRA THERAPEUTICS INC

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

ZVRA$12.14+4.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Zevra Therapeutics, Inc.
Dated: April 1, 2024	By:	/s/ Neil F. McFarlane
		Neil F. McFarlane
		President and Chief Executive Officer (Principal Executive Officer)
Dated: April 1, 2024	By:	/s/ R. LaDuane Clifton
		R. LaDuane Clifton, MBA, CPA
		Chief Financial Officer, Secretary and Treasurer (Principal Financial Officer)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.